Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

107.34 USD -0.38 (-0.35%)
Official Closing Price Updated: 4:02 PM EDT, Sep 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals
- 65% of respondents said they were not prepared to have their eyesight worsen as they got older 
From PR Newswire
AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress
- New analyses will highlight head-to-head trial evaluating safety and efficacy of RINVOQ® (upadacitinib) versus dupilumab in specific body regions of patients with moderate to severe atopic... 
From PR Newswire
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
- In three pivotal Phase 3 studies, risankizumab-rzaa demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1],[2],[3] 
From PR Newswire
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
- Significantly more upadacitinib patients achieved the primary and all secondary endpoints compared to placebo in Phase 3 induction and maintenance studies supporting the submissions[1-3] 
From PR Newswire
AbbVie and REGENXBIO Announce Eye Care Collaboration
- AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise 
From PR Newswire
Global Interleukin Inhibitors Market to be Driven by increase in the chronic inflammatory diseases in the Forecast Period of 2021-2026
Tags English Extended Distribution Research Newswire
From iCrowdNewswire
AbbVie Declares Quarterly Dividend
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. 
From PR Newswire
AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021
--Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson's disease 
From PR Newswire
AbbVie to Present at the Morgan Stanley Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021. Richard A. Gonzalez, chairman and chief executive officer,... 
From PR Newswire
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and... 
From Business Wire News Releases
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
- Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma... 
From PR Newswire
AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress
--Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine 
From PR Newswire
European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
- Approval supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis evaluating RINVOQ (upadacitinib) monotherapy or with topical corticosteroids[1] 
From PR Newswire
New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine
- In the atogepant Phase 3 ADVANCE trial, participants experienced a significant reduction in migraine and headache days across 12 weeks of treatment¹ 
From PR Newswire
SANUWAVE Inc. Assets Get Another Valuation Boost Following NanoVibronix Making Shockwave Therapy Available OTC (OTC: SNWV)
Tags Financial Market Technology Health & Medicine
From AB Newswire
SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe 
From PR Newswire
Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone
Mission Therapeutics (“Mission”), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”)(NYSE: ABBV) today announced progression of selected... 
From Business Wire News Releases
JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults
- Upadacitinib (30 mg, once daily) monotherapy demonstrated significantly greater rates of skin clearance improvement and itch reduction compared to dupilumab (300 mg, every other week) monotherapy at... 
From PR Newswire
AbbVie Reports Second-Quarter 2021 Financial Results
- Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis; Adjusted Diluted EPS of $3.11 
From PR Newswire
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
-- 6.7 million adults in the U.S. are living with spasticity across a variety of neurologic conditions 
From PR Newswire
AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
- Extension builds on partnership established in 2014, extended in 2018 
From PR Newswire
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
- If approved, AGN-190584 is expected to be the first eye drop for the treatment of presbyopia, the eye's reduced ability to focus on near objects 
From PR Newswire
DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients
- DALVANCE® is the first and only single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth 
From PR Newswire
Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)
- This is the sixth BTD granted for venetoclax as AbbVie continues to show ongoing commitment across blood cancers including tough to treat myeloid malignancies 
From PR Newswire
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting
- Data presentations highlight Phase 3 GEMINI 1 trial results on the safety and efficacy of investigational AGN-190584 (pilocarpine 1.25%) as a potential novel treatment for presbyopia, a common and... 
From PR Newswire
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) did not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental New Drug Application (sNDA) for... 
From PR Newswire
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
From GlobeNewswire News Releases
AbbVie to Host Second-Quarter 2021 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m.... 
From PR Newswire
Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
- Significantly more upadacitinib-treated (15 mg or 30 mg, once daily) patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to patients on placebo at one-year... 
From PR Newswire
AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO)
- Data being presented at the 16th Congress of ECCO include Phase 3 analyses from the upadacitinib (RINVOQ®) and risankizumab (SKYRIZI®) clinical trial programs 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.